Chemotherapy-Induced Lymphodepletion Prior to CAR-T Therapy in Lymphoma

Overview

Lymphodepletion (LD) chemotherapy, primarily with fludarabine and cyclophosphamide (FluCy), is a critical preparative step before CAR-T cell therapy in refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL). LD enhances CAR-T cell expansion, persistence, and efficacy by modulating host immune cells and the tumor microenvironment, thereby improving clinical outcomes.

Background

CAR-T cell therapy involves genetically engineered T-lymphocytes targeting tumor-specific antigens such as CD19 in B-NHL. Autologous CAR-T therapies have become standard of care for refractory or relapsed B-NHL since 2018, with four FDA-approved products available. Despite this, durable responses occur in less than half of patients, influenced by factors including tumor burden, CAR-T cell characteristics, and the lymphodepletion regimen used prior to infusion. LD chemotherapy facilitates CAR-T engraftment and expansion by depleting endogenous immune cells and altering the tumor microenvironment.

Data Highlights

Key Findings

• Fludarabine and cyclophosphamide (FluCy) is the most commonly used and effective lymphodepletion regimen prior to CAR-T therapy in B-NHL.
• LD enhances CAR-T cell expansion, peak levels, and persistence, which correlate with improved clinical responses.
• LD depletes endogenous immune cells including regulatory T-cells, reducing competition for homeostatic cytokines (IL-7, IL-15) and improving CAR-T function.
• LD induces immunogenic tumor cell death and downregulates immunosuppressive enzymes such as indoleamine 2,3-dioxygenase (IDO), enhancing CAR-T efficacy.
• Clinical trials (e.g., JULIET) demonstrate superior response rates and survival outcomes with FluCy compared to alternative LD regimens or no LD.
• Optimal Flu exposure (AUC) is important for balancing efficacy and toxicity in lymphodepletion.

Clinical Implications

Clinicians should employ FluCy lymphodepletion prior to CAR-T cell infusion in patients with refractory or relapsed B-NHL to maximize CAR-T expansion and therapeutic efficacy. Monitoring and optimizing Flu exposure may improve outcomes while minimizing toxicity. Understanding the immunomodulatory effects of LD can guide supportive care and patient selection.

Conclusion

Lymphodepletion with fludarabine and cyclophosphamide is a pivotal component of CAR-T therapy protocols in lymphoma, enhancing CAR-T cell engraftment and antitumor activity. Its immunomodulatory effects contribute significantly to improved clinical outcomes in refractory and relapsed B-NHL.

References

1. Neelapu et al. 2017 -- Axicabtagene ciloleucel CAR-T therapy in refractory large B-cell lymphoma
2. Schuster et al. 2019 -- Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
3. Locke et al. 2019 -- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma
4. Wang et al. 2020 -- Brexucabtagene autoleucel in mantle cell lymphoma
5. Gauthier et al. 2021 -- Lymphodepletion chemotherapy prior to CAR-T cell therapy